Genmab A/S (GNMSF) — 6-K Filings

6-K Filings (50)

• Genmab A/S Files 6-K, Incorporates by Reference — Dec 29, 2025 Risk: low
  Genmab A/S filed a Form 6-K on December 29, 2025, to report company announcements. This filing is incorporated by reference into several of Genmab's existing S-
• Genmab A/S Files 6-K, Incorporates by Reference — Dec 12, 2025 Risk: low
  Genmab A/S filed a Form 6-K on December 12, 2025, to report company announcements. This filing is incorporated by reference into several of Genmab's existing Fo
• Genmab A/S Files 6-K on Share Transactions — Dec 1, 2025 Risk: low
  On December 1, 2025, Genmab A/S filed a Form 6-K, reporting transactions with shares and linked securities. This filing is incorporated by reference into severa
• Genmab A/S Files 6-K, Incorporates Updates into S-8 Filings — Nov 26, 2025 Risk: low
  Genmab A/S filed a Form 6-K on November 26, 2025, to report updates. This filing is incorporated by reference into several of Genmab's S-8 registration statemen
• Genmab Grants Stock Units and Warrants to Employees — Nov 20, 2025 Risk: low
  On November 20, 2025, Genmab A/S announced the grant of restricted stock units and warrants to employees. This filing is a Form 6-K report for the month of Nove
• Genmab A/S Files Form 6-K with Updated Articles of Association — Nov 19, 2025 Risk: low
  Genmab A/S filed a Form 6-K on November 19, 2025, to report updates. This filing includes their Articles of Association as Exhibit 3.1. The company is registere
• Genmab A/S Files 6-K, Incorporates by Reference — Nov 18, 2025 Risk: low
  Genmab A/S filed a Form 6-K on November 18, 2025, to report company announcements. This filing is incorporated by reference into several of Genmab's existing S-
• 6-K Filing — Nov 12, 2025
• 6-K Filing — Nov 6, 2025
• Genmab Reports Strong DARZALEX® Q3 Sales — Oct 17, 2025 Risk: low
  Genmab A/S announced on October 14, 2025, that net sales of its drug DARZALEX® (daratumumab) for the third quarter of 2025 exceeded expectations. The company is
• Genmab A/S Files 6-K, Incorporates Articles of Association — Sep 30, 2025 Risk: low
  Genmab A/S filed a Form 6-K on September 30, 2025, for the month of September 2025. This report is incorporated by reference into several of Genmab's S-8 regist
• Genmab to Acquire Merus for $1.5B — Sep 29, 2025 Risk: medium
  On September 29, 2025, Genmab A/S announced its intention to acquire Merus N.V. for approximately $1.5 billion. This acquisition aims to expand Genmab's late-st
• Genmab Grants Stock Units and Warrants to Employees — Sep 26, 2025 Risk: low
  On September 26, 2025, Genmab A/S announced the grant of restricted stock units and warrants to employees. This filing is a Form 6-K report for the month of Sep
• Genmab A/S Files 6-K: Major Shareholder Announcement — Sep 23, 2025 Risk: low
  Genmab A/S filed a Form 6-K on September 23, 2025, reporting a major shareholder announcement dated September 23, 2025. This filing is incorporated by reference
• Genmab A/S Files 6-K, Incorporates into S-8 Filings — Sep 10, 2025 Risk: low
  Genmab A/S filed a Form 6-K on September 10, 2025, to report updates. This filing is incorporated by reference into several of Genmab's existing S-8 registratio
• Genmab A/S Capital Increase from Employee Warrant Exercise — Sep 9, 2025 Risk: low
  On September 9, 2025, Genmab A/S announced a capital increase of approximately DKK 1.1 million (USD 0.16 million) due to the exercise of employee stock options.
• Genmab A/S Files 6-K, Incorporates Articles of Association — Aug 13, 2025 Risk: low
  Genmab A/S filed a Form 6-K on August 13, 2025, to report updates. This filing is incorporated by reference into several of Genmab's S-8 registration statements
• Genmab A/S Reports Capital Increase from Warrant Exercise — Aug 12, 2025 Risk: low
  Genmab A/S announced on August 12, 2025, a capital increase resulting from the exercise of employee stock warrants. The company filed a Form 6-K to report this
• Genmab's EPCORE Trial Hits Key Endpoints in DLBCL Study — Aug 7, 2025 Risk: medium
  Genmab A/S announced on August 7, 2025, that its Phase 3 EPCORE FL-1 clinical trial met its dual primary endpoints. This trial evaluated epcoritamab in combinat
• Genmab Reports Strong DARZALEX® Sales for Q2 2025 — Jul 16, 2025 Risk: low
  Genmab A/S announced on July 16, 2025, that net sales of its drug DARZALEX® (daratumumab) for the second quarter of 2025 exceeded expectations. The company did
• Genmab Completes Share Buy-back Program — Jun 30, 2025 Risk: low
  Genmab A/S announced the completion of its share buy-back program on June 30, 2025. The program involved the repurchase of shares, details of which are provided
• Genmab A/S Announces Share Buy-back Program Transactions — Jun 23, 2025 Risk: low
  On June 23, 2025, Genmab A/S announced transactions related to its share buy-back program. This Form 6-K filing incorporates by reference previous registration
• Genmab A/S Files 6-K with Updated Articles of Association — Jun 18, 2025 Risk: low
  Genmab A/S filed a Form 6-K on June 18, 2025, to report updates. This filing is incorporated by reference into several of Genmab's S-8 registration statements,
• Genmab A/S Files 6-K on Share Transactions — Jun 17, 2025 Risk: low
  On June 17, 2025, Genmab A/S filed a Form 6-K, incorporating by reference a company announcement dated June 17, 2025, regarding transactions with its shares and
• Genmab Buys Back 1M Shares for DKK 230M — Jun 16, 2025 Risk: low
  On June 16, 2025, Genmab A/S announced transactions related to its share buy-back program. The company purchased 1,000,000 shares of its own stock at an average
• Genmab A/S Grants Stock Units and Warrants to Employees — Jun 12, 2025 Risk: low
  On June 12, 2025, Genmab A/S announced the grant of restricted stock units and warrants to employees. This filing is a Form 6-K report, which is a report of for
• Genmab A/S Announces Share Buy-back Program Update — Jun 10, 2025 Risk: low
  On June 10, 2025, Genmab A/S announced transactions related to its share buy-back program. The company is filing this report on Form 6-K to provide updates on t
• Genmab A/S Files 6-K on Share Buy-back Program — Jun 2, 2025 Risk: low
  On June 2, 2025, Genmab A/S announced transactions related to its share buy-back program. The company is filing this report on Form 6-K to incorporate by refere
• Genmab A/S Announces Share Buy-back Program Transactions — May 27, 2025 Risk: low
  On May 26, 2025, Genmab A/S announced transactions related to its share buy-back program. The company purchased shares as part of this ongoing program, details
• Genmab A/S Files 6-K, Incorporates into S-8 Filings — May 21, 2025 Risk: low
  Genmab A/S filed a Form 6-K on May 21, 2025, to report updates. This filing is incorporated by reference into several of Genmab's S-8 registration statements, i
• Genmab Announces Capital Increase From Warrant Exercise — May 20, 2025 Risk: low
  Genmab A/S announced on May 20, 2025, a capital increase resulting from the exercise of employee stock warrants. This action will lead to the issuance of new sh
• Genmab Completes DKK 2.5B Share Buy-back — May 19, 2025 Risk: low
  Genmab A/S announced on May 19, 2025, that it has completed a share buy-back program. The company repurchased a total of 1,000,000 shares at an average price of
• Genmab Buys Back Shares Worth DKK 250M — May 12, 2025 Risk: low
  On May 12, 2025, Genmab A/S announced transactions related to its share buy-back program. The company purchased 1,000,000 shares of its own stock at an average
• Genmab A/S Files 6-K with Interim Report — May 8, 2025 Risk: low
  Genmab A/S filed a Form 6-K on May 8, 2025, to report its interim financial information as of that date. This filing is incorporated by reference into several o
• Genmab Buys Back Shares Worth DKK 2.4B — May 5, 2025 Risk: low
  On May 5, 2025, Genmab A/S announced transactions related to its share buy-back program. The company purchased 1,000,000 shares of its own stock at an average p
• Genmab to File sBLA for Epcoritamab with FDA — May 2, 2025 Risk: low
  Genmab A/S announced on May 2, 2025, that it will submit a Supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for
• Genmab Completes DKK 2.5B Share Buy-back — Apr 28, 2025 Risk: low
  Genmab A/S announced on April 28, 2025, that it has completed a share buy-back program. The company repurchased a total of 1,000,000 shares at an average price
• Genmab A/S Files Form 6-K for April 2025 — Apr 22, 2025 Risk: low
  Genmab A/S filed a Form 6-K on April 22, 2025, to report information for the month of April 2025. This filing is incorporated by reference into Genmab's existin
• Genmab A/S Files 6-K, Incorporates into S-8 Filings — Apr 15, 2025 Risk: low
  Genmab A/S filed a Form 6-K on April 15, 2025, to report information as a foreign private issuer. This filing is incorporated by reference into several of Genma
• Genmab A/S Files Form 6-K for April 2025 — Apr 14, 2025 Risk: low
  Genmab A/S filed a Form 6-K on April 14, 2025, to report information for the month of April 2025. This report is incorporated by reference into several of Genma
• Genmab A/S Files 6-K, Incorporates into S-8 Filings — Apr 10, 2025 Risk: low
  Genmab A/S filed a Form 6-K on April 10, 2025, to report information as a foreign private issuer. This filing is incorporated by reference into several of Genma
• Genmab A/S Files Form 6-K for April 2025 — Apr 7, 2025 Risk: low
  Genmab A/S filed a Form 6-K on April 7, 2025, to report information for the month of April 2025. This report is incorporated by reference into several of Genmab
• Genmab A/S Files April 2025 6-K Report — Apr 1, 2025 Risk: low
  Genmab A/S filed a Form 6-K on April 1, 2025, to report information for the month of April 2025. This report is incorporated by reference into several of Genmab
• Genmab A/S Files March 2025 6-K Report — Mar 31, 2025 Risk: low
  Genmab A/S filed a Form 6-K on March 31, 2025, to report for the month of March 2025. This filing is incorporated by reference into several of Genmab's S-8 regi
• Genmab A/S Files March 2025 6-K Report — Mar 25, 2025 Risk: low
  Genmab A/S filed a Form 6-K on March 25, 2025, to report information for the month of March 2025. This filing is incorporated by reference into several of Genma
• Genmab A/S Files 6-K Report — Mar 24, 2025 Risk: low
  Genmab A/S filed a Form 6-K on March 24, 2025, to report information for the month of March 2025. This filing is incorporated by reference into several of Genma
• Genmab A/S Files March 2025 6-K Report — Mar 20, 2025 Risk: low
  Genmab A/S filed a Form 6-K on March 20, 2025, to report information for the month of March 2025. This filing is incorporated by reference into several of Genma
• Genmab A/S Files March 2025 6-K Report — Mar 12, 2025 Risk: low
  Genmab A/S filed a Form 6-K on March 12, 2025, to report information for the month of March 2025. This filing is incorporated by reference into several of Genma
• Genmab A/S Files March 2025 6-K Report — Mar 10, 2025 Risk: low
  Genmab A/S filed a Form 6-K on March 10, 2025, to report information for the month of March 2025. This filing is incorporated by reference into several of Genma
• Genmab A/S Files Form 6-K for March 2025 — Mar 6, 2025 Risk: low
  Genmab A/S filed a Form 6-K on March 6, 2025, to report information for the month of March 2025. This filing is incorporated by reference into several of Genmab

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX